A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
This research study is investigating a new medication called sotatercept for people living with pulmonary arterial hypertension (PAH). PAH is a condition where blood pressure in the arteries leading to the lungs is too high. This particular study is an extension of an earlier study (MK-7962-024, also known as LIGHTRAY) that looked at how safe and effective sotatercept was. Now, researchers want to continue learning more about sotatercept, specifically when it's given in doses that are adjusted based on a person's weight group. The main goal is to understand if these weight-based doses are safe and well-tolerated by participants over a longer period.
एक नजर में
यह अध्ययन किस बारे में है?
Pulmonary arterial hypertension, often called PAH, is a serious condition where the blood vessels in your lungs become narrow, making it harder for your heart to pump blood through them. This can lead to symptoms like breathlessness and tiredness. Researchers are urgently looking for new and better ways to treat PAH to help people feel better and live longer.
This study is focusing on a new medicine called sotatercept. We know from earlier research that sotatercept shows promise in treating PAH. A previous study, called LIGHTRAY, already looked into how safe sotatercept was and how well it worked for people with PAH. That study also explored different ways of giving the medicine, either based on a person's exact weight or using doses that fit within certain weight ranges.
This new study, called LIGHTRAY EXTENSION, is for people who took part in the original LIGHTRAY study. It's a chance for them to continue receiving sotatercept. The main aim here is to understand if giving sotatercept in doses based on weight groups (rather than exact weight) is safe and if people can continue taking it over a longer period without significant problems. This helps doctors understand the long-term effects and how best to give the medicine if it becomes widely available.
मुख्य निष्कर्ष
- This study is for people previously in the LIGHTRAY study for PAH.
- It aims to learn more about the long-term safety of sotatercept.
- Sotatercept doses will be based on weight groups (weight-banded).
- It's a research study, not standard treatment.
- All participants will continue to receive sotatercept.
कौन पात्र हो सकता है?
To join this particular study, you must have already taken part in the previous LIGHTRAY study (MK-7962-024) and completed the treatment period there. You should not have stopped taking the study medicine in that previous study and must be considered safe to continue in this extension study.
It's also important that you haven't started taking sotatercept that is bought from a chemist or prescribed normally, as this study is still part of the research process. You also shouldn't be taking any other similar medicines that work in the same way as sotatercept.
Anyone aged 18 years and older, male or female, who meets these criteria may be able to join. Your study doctor will check all these points to see if this study is suitable for you.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Did you complete the previous LIGHTRAY study (MK-7962-024)?
- Did you stay on the study treatment throughout that previous study?
- Are you currently not taking commercially available sotatercept?
- Are you not taking any other similar activin signalling inhibitor medicines?
भागीदारी में क्या शामिल है?
If you join this study, you will continue to receive the study medicine, sotatercept, which will be given in doses based on your weight group. You will also continue with any other PAH treatments your doctor has prescribed, as sotatercept is meant to be an add-on treatment. You will have regular visits to the clinic so the study team can monitor your health, check for any side effects, and make sure the treatment is working well. These visits will involve various checks, including physical exams, blood tests, and possibly other tests related to your heart and lung health. The study aims to follow participants for a longer time to understand the long-term safety of sotatercept when given using a weight-based dosing plan. The specific number and frequency of visits, and the total duration you'll be in the study, will be fully explained by the study team.
संभावित जोखिम और लाभ
स्थान (73)
- University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930)सत्यापित पोस्टकोडऑरोरा, संयुक्त राज्य अमेरिका
- University of Kansas Medical Center ( Site 1928)सत्यापित पोस्टकोडकैनसस सिटी, संयुक्त राज्य अमेरिका
- University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916)सत्यापित पोस्टकोडअल्बुकर्क, संयुक्त राज्य अमेरिका
- Centro Medico Capital ( Site 0002)सत्यापित पोस्टकोडLa Plata, Argentina
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0006)सत्यापित पोस्टकोडMar del Plata, Argentina
- Instituto Medico Rio Cuarto ( Site 0010)सत्यापित पोस्टकोडRío Cuarto, Argentina
- Instituto de Cardiologia Juana F. Cabral ( Site 0008)सत्यापित पोस्टकोडCorrientes, Argentina
- Hospital Provincial Jose Maria Cullen ( Site 0005)सत्यापित पोस्टकोडSanta Fe, Argentina
- Royal Prince Alfred Hospital ( Site 0103)सत्यापित पोस्टकोडCamperdown, Australia
- Westmead Hospital ( Site 0100)सत्यापित पोस्टकोडवेस्टमीड, ऑस्ट्रेलिया
- Wesley Research Institute ( Site 0101)सत्यापित पोस्टकोडAuchenflower, Australia
- The Alfred Hospital ( Site 0102)सत्यापित पोस्टकोडमेलबर्न, ऑस्ट्रेलिया
सामान्य प्रश्न
फुफ्फुसीय धमनी उच्च रक्तचाप (PAH) क्या है?
PAH is a serious condition where blood pressure in the arteries leading to the lungs becomes too high, making it hard for the heart to pump blood.
What is sotatercept?
Sotatercept is a new medicine being studied as a treatment for PAH. It's not yet available as a standard treatment.
Why is this an 'extension' study?
It's for people who were already in a previous study looking at sotatercept for PAH. It allows them to keep taking the medicine and helps researchers gather more long-term information.
इस अध्ययन में कौन शामिल हो सकता है?
Only people who finished the previous LIGHTRAY study safely and without stopping the study medicine are eligible for this extension study.
Are there different doses of sotatercept?
Yes, in this study, sotatercept will be given in doses that are adjusted based on a person's weight group.
और अधिक जानने के लिए कैसे पता करें
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.